PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Disease ReportsMyelodysplastic-myeloproliferative diseases
MeSH D054437 - myelodysplastic-myeloproliferative diseases
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
D001855:Bone marrow diseases
$
Success rate
D054437: 
Myelodysplastic-myeloproliferative diseases
$
Success rate
D015477:Myelomonocytic leukemia chronic
$
Success rate
D054429:Myelomonocytic leukemia juvenile
0 Companies
0 Drugs
Success rate
D054438:Leukemia myeloid chronic atypical bcr-abl negative
0 Companies
0 Drugs
Success rate
Events Timeline
Loading
Commercial
Company Name
Drug Name
Trade Name
Patent Expires
Approval Date
Revenue
Period
TevaImatinib Imatinib  2016-08-04   
Imatinib Imatinib Teva  2013-01-07   
Imatinib Imatinib Teva B.V  2017-11-15   
MylanImatinib Imatinib  2017-06-21   
NovartisImatinib Gleevec  2001-05-10 $887 M Q2/20-Q2/23 
Imatinib Glivec  2001-11-07   
Dr Reddys LaboratoriesImatinib Imatinib  2018-08-13   
Zydus TherapeuticsImatinib Imatinib  2020-04-08   
Sun Pharmaceutical IndustriesImatinib Imatinib  2015-12-03   
ApotexImatinib Imatinib  2016-08-05   
Breckenridge PharmaceuticalImatinib Imatinib  2019-02-08   
Amneal PharmaceuticalsImatinib Imatinib  2019-02-08   
NATCO PharmaImatinib Imatinib  2019-03-01   
1
2
>
Clinical Trials
Historical Success Rate
Phase 1
79%
27/34
Phase 2
26%
12/47
Phase 3
14%
2/14
Approved: 2Overall Success rate: 3%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name
Phase 1
Phase 2
Phase 3
Phase 4
Drug Name
Teva
1
2
>
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use